drugset / Trial / NCT05330182
LMN-201 for Prevention of C. Difficile Infection Recurrence
Phase 2/3
Recruiting
375 enrolled
Lumen Bioscience, Inc.
Congressionally Directed Medical Research Programs · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This is a multisite study to evaluate the safety, tolerability, and efficacy of LMN-201 in participants recently diagnosed with CDI who are scheduled to receive or are receiving SOC antibiotic therapy against C. difficile.
Timeline
- Start
- 2024-08-29
- Primary completion
- 2027-06-01
- Completion
- 2027-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LMN-201 | Other / unclassified | — | Oral |